Author(s)
Mennini FS1, Andreoni M2, Sarmati L3, Bini C4, Espin J5, Horcajada Gallego P6, Czypionka T7, Favato G8, Marcellusi A1
1Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, 2University of Rome, Rome, Italy, 3University of Rome “Tor Vergata”, Rome, Italy, 4Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Roma, Italy, 5Andalusian School of Public Health, Granada, Spain, 6Department of Infectious Diseases Hospital del Mar, Barcelona, Spain, 7Institute for Advanced Studies, Wien, Austria, 8Institute for Leadership and Management in Health, Kingston University, London, SRY, UK
OBJECTIVES: This study aimed to evaluate the direct costs for the management of ABSSSI in non-severe patients treated with standard antibiotics therapy or innovative long-acting dalbavancin treatment in hospital for Italy, Spain and Austria. METHODS: A Budget Impact Analysis was developed to evaluate the direct costs associated with the management of ABSSSI from the national public health system perspective. The model considers the possibility to early discharge patients directly from the Emergency Department (ED), after one, or after 2 or 3 night in the hospital. A scenario with Standard of Care was compared with dalbavancin scenario, where patients had the possibility of being early discharged. The epidemiological and cost parameters were extrapolated from national administrative databases and from a systematic literature review for each Country. The analysis was conducted in a 3-year time horizon. RESULTS: The model estimated an average annual number of patients with non-severe ABSSSI in Italy, Spain and Austria equal to 5,396, 7,884 and 1,788 respectively. A total annual expenditure of about € 9.9 million, € 13.5 million and € 3.4 million was estimated for treating the full set of ABSSSI patients in Italy, Spain and Austria respectively. Dalbavancin reduces the in-hospital length of stay in each Country. In the first year of its introduction, Dalbavancin could significantly reduce the total economic burden in Italy and Spain (-€ 352,252 and -€ 233,991) while it could increase the total economic burden in Austria (€ 80,769, 0.7% of the total expenditure for these patients); in the third year of its introduction, Dalbavancin could reduce the total economic burden in each Country (-€ 1,1 million, -€ 810,650, -€ 70,269 respectively). CONCLUSIONS: The introduction of dalbavancin in a new patients pathway to treat non-severe aBSSSI, could generate a significant reduction of hospitalized patients and the overall patient's length of stay in hospital.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
PMU29
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Multiple Diseases
